FT Reporting that ABBV is in advanced talks to acquire Apogee Therapeutics for ~$11bn
Report Coverage
- Broker
- JPMorgan
- Region
- United States
- Sector
- Healthcare & Biotech
- Report Type
- Market Report
- Primary Focus
- FT Reporting that ABBV is in advanced talks to acquire Apogee Therapeutics for ~$11bn
Full Report Document Access
This page is a research report summary and access guidance page. If you are searching for JPMorgan FT Reporting that ABBV is in advanced talks to acquire Apogee Therapeutics for ~$11bn research report PDF or the full report document, use the summary, coverage fields and related links to confirm relevance before requesting VIP access. Full PDF report access is available to VIP members after request confirmation; the PDF is not publicly displayed on this page.
Report Summary
Overview:Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well- established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart (APG777), the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing thr
Key Takeaways
- Phase 3: Amlitelimab, an OX40L mAb, by Sanofi; and rocatinlimab, a T-cell rebalancing mAb that targets the OX40 receptor,
- Phase 2: rezpegaldesleukin, an anti-IL-2, by NEKTAR; temptokibart, an anti-IL-22R, by LEO Pharma; KT-621, an oral STAT6
- Phase 3: GB-0895, a TSLP mAb, by Generate Bio; and
- Phase 2: Lunsekimig, a IL-13/TSLP nanobody, by Sanofi, PF-07275315, an anti-IL-4/IL-13/TSLP multispecific, by Pfizer,
- Phase 3: mepolizumab, an anti-IL-5 mAb from GSK; itepekimab, an anti-IL-33 mAb from Sanofi/Regeneron; tozorakimab, an
Why This Report Matters
JPMorgan's 7-page analysis on "FT Reporting that ABBV is in advanced talks to acquire Apogee Therapeutics for ~$11bn" provides institutional-grade insights for investors and professionals seeking to understand current market dynamics and investment implications in this space.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the JPMorgan FT Reporting that ABBV is in advanced talks to acquire Apogee Therapeutics for ~$11bn report. It helps users review FT Reporting that ABBV is in advanced talks to acquire Apogee Therapeutics for ~$11bn coverage, key takeaways, and related broker or sector research paths across Acquisition, Reporting, ABBV; Neetu Jhamb, Specialist Sales.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.